Performance Targets

Under HOPE 100 Stage 1, in addition to quantitative performance targets, the Kyorin Group also aims to contribute to stakeholders. We have recognized that to achieve sound, sustained growth we need to strengthen our management base by balancing investments for growth, investments for business continuity, and shareholder returns.

We therefore plan to make aggressive investments for growth, acquire new business and products to reinforce the research and development pipeline in our core pharmaceutical business and proactively make strategic investments in new consumer healthcare operations. In deciding dividends we target a consolidated payout ratio of 30%.